Cornerstone Wealth Group LLC Boosts Holdings in Boston Scientific Corporation $BSX

Cornerstone Wealth Group LLC raised its position in Boston Scientific Corporation (NYSE:BSX) by 1,323.9% in the 1st quarter, Holdings Channel.com reports. The fund owned 64,233 shares of the medical equipment provider’s stock after acquiring an additional 59,722 shares during the quarter. Cornerstone Wealth Group LLC’s holdings in Boston Scientific were worth $3,823,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BSX. Border to Coast Pensions Partnership Ltd purchased a new position in Boston Scientific during the 1st quarter worth $24,341,000. Pictet Asset Management Holding SA boosted its holdings in Boston Scientific by 19.1% in the first quarter. Pictet Asset Management Holding SA now owns 5,120,057 shares of the medical equipment provider’s stock worth $321,301,000 after acquiring an additional 820,284 shares in the last quarter. Cambient Family Office LLC grew its stake in shares of Boston Scientific by 30.1% during the first quarter. Cambient Family Office LLC now owns 3,699 shares of the medical equipment provider’s stock worth $232,000 after acquiring an additional 855 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC increased its holdings in shares of Boston Scientific by 56.9% during the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 8,452 shares of the medical equipment provider’s stock valued at $530,000 after acquiring an additional 3,065 shares in the last quarter. Finally, VCI Wealth Management LLC increased its holdings in shares of Boston Scientific by 55.2% during the first quarter. VCI Wealth Management LLC now owns 24,261 shares of the medical equipment provider’s stock valued at $1,522,000 after acquiring an additional 8,632 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $44.16 on Friday. Boston Scientific Corporation has a twelve month low of $43.89 and a twelve month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market cap of $65.64 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56. The company’s 50 day moving average is $52.87 and its 200 day moving average is $71.13.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has approved a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $65.00 target price on shares of Boston Scientific in a research note on Tuesday, June 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $77.00 price target on shares of Boston Scientific in a report on Monday, May 18th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Weiss Ratings lowered shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, Oppenheimer set a $90.00 target price on Boston Scientific in a research report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $83.36.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 9,800 shares of company stock worth $554,012 over the last three months. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.